Pyxis Oncology, Inc..
PYXS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Pyxis Oncology, Inc. is a clinical stage oncology company focused on developing antibody-drug conjugates (ADCs) and immunotherapies to treat difficult-to-treat cancers. Their approach involves targeting the tumor microenvironment and directly targeting tumor cells. The company's pipeline includes se...Show More
Better Health for All
0
No evidence available to assess Pyxis Oncology, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Pyxis Oncology, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Pyxis Oncology, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points related to fair trade and ethical sourcing, such as fair-trade certification share, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, high-risk materials spend, or a quantifiable percentage for supplier diversity spend, were found in the provided articles.
1
Honest & Fair Business
0
No relevant information was available in the provided articles to assess Pyxis Oncology, Inc. against the 'Honest & Fair Business' ethical value.
1
All articles contained error messages and no factual content.
2
Kind to Animals
-60
Pyxis Oncology engages in animal testing for product safety.
1
The company uses *in vitro* (cell-based) assays and a 3D liver spheroid model for early-stage cytotoxicity, binding affinity, and hepatotoxicity assessments, covering early-stage toxicity screens.
2
Animal studies, including those involving mice and cynomolgus monkeys, are conducted.
3
These studies are approved by the Pfizer Institutional Animal Care and Use Committee (IACUC) or local regulatory authorities and follow guidelines such as the "Guide for the Care and Use of Laboratory Animals."
4
Nonhuman primate studies are conducted in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)–accredited institution.
5
However, the company's policy on animal testing is not explicitly detailed beyond adherence to guidelines and approvals, and there is no mention of transparent reduction targets for animal testing volume. The company is listed by Cruelty Free Investing for exploiting animals due to its engagement in animal testing.
6
No War, No Weapons
-20
The company's Code of Business Conduct and Ethics states a policy of compliance with U.S. Embargoes, which generally prohibit doing business with countries subject to U.S. government sanctions, including Cuba, Iran, North Korea, Syria, and the Crimea Region of Ukraine, as well as specific sanctioned entities.
1
Planet-Friendly Business
0
No evidence available to assess Pyxis Oncology, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles, primarily legal and financial filings or internal policy documents, do not contain specific, quantifiable evidence directly addressing the company's performance on any of the KPIs related to "Respect for Cultures & Communities." Information regarding partnerships with indigenous or local community groups, community investments, cultural incident management, local employment ratios, or grievance mechanisms specifically for community concerns is either absent, too vague, or refers to internal corporate compliance rather than external community engagement as defined by the rubric. Therefore, no KPIs can be scored based on the provided evidence.
Safe & Smart Tech
-20
The company allows users to contact it to delete, update, or correct their information, which aligns with industry-standard user privacy controls.
1
Pyxis Oncology products were found to have critical vulnerabilities, including default credentials (CVSS v3 base score of 8.8) and a 'Not Using Password Aging' issue, which could allow privileged access to the file system and ePHI.
2
BD, the parent company, alerted CISA, the FDA, and ISACs about these vulnerabilities.
3
Remediation for some products was planned for June and August 2022, indicating critical vulnerabilities were patched within 30-45 days on average.
4
The company's privacy policy also references California opt-out rights, indicating basic compliance with applicable regulations.
5
Zero Waste & Sustainable Products
0
No evidence available to assess Pyxis Oncology, Inc. on Zero Waste & Sustainable Products.